Mapsin Expression in Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma
American Journal of Life Sciences
Volume 2, Issue 3, June 2014, Pages: 182-189
Received: Jun. 9, 2014; Accepted: Jun. 13, 2014; Published: Jun. 30, 2014
Views 3045      Downloads 115
Sahar Mohamed El-Sheikh, Professor of oral pathology, Faculty of dentistry, Alexandria University, Egypt
Amani Noureldin Abd El-Latif, Associatte professor of oral pathology, Faculty of dentistry, Pharos University, Alexandria, Egypt
Article Tools
Follow on us
Salivary gland tumors comprise a significant proportion of oral tumors. Maspin is a non-inhibitory serine protease inhibitor (serpin). It is supposed to suppress tumor-induced angiogenesis, tumor cell motility, invasion and metastasis. Objectives: To evaluate salivary gland tumors clinically, investigate the immunoexpression of maspin in mucoepidermoid and adenocystic carcinoma of the salivary gland tumors and to detect the correlation of maspin expression with biological behavior of these tumors.Materials and methods: Fourteen cases of malignant salivary gland tumors were retrieved from the Oral Pathology files of Faculty of Dentistry, Alexandria University, Egypt. The study included eight cases of mucoepidermoid carcinoma, six cases of adenoid cystic carcinoma. Two specimens of normal salivary tissue were taken as control.Results: The difference in mean optical density of maspin expression between low-grade and high-grade MEC was calculated. Optical density was higher in low-grade type compared to the high grade one with a significant difference (P< 0.05).Moreover, the results of this study showed difference between the MOD of adenoid cystic carcinoma subtypes, with the solid subtype expressing the lowest percentage. Conclusion: Maspin protein is overexpressed in low grade malignant salivary gland tumors, and decrease as the histological malignancy rises so it can be used as prognostic marker in salivary gland carcinoma. In addition, maspin could serve as a therapeutic target in salivary gland tumors including recombinant protein or gene therapy.
Mucoepidermoid Carcinoma, Adenoid Cystic Carcinoma, Maspin
To cite this article
Sahar Mohamed El-Sheikh, Amani Noureldin Abd El-Latif, Mapsin Expression in Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma, American Journal of Life Sciences. Vol. 2, No. 3, 2014, pp. 182-189. doi: 10.11648/j.ajls.20140203.18
Brandwein MS, Ferlito A, Bradley PJ, Hille JJ, Rinaldo A. Diagnosis and classification of salivary neoplasms: pathologic challenges and relevance to clinical outcomes. Acta Otolaryngol 2002; 122(7):758-64.
Pinkston JA, Cole P. Incidence rates of salivary gland tumors: results from a population-based study. Otolaryngol Head Neck Surg 1999; 120(6):834-40.
Speight PM, Barrett AW. Salivary glandtumors. Oral Dis 2002;8(5):229-40.
Califano J, EiseleDW. Benign salivary gland neoplasms. OtolaryngolClin North Am 1999; 32(5):861-73.
Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization Classification of Tumors: Pathology and Genetics of Head and Neck Tumors. Lyon: IARC Press; 2005.
Speight PM, Barrett AW. Prognosticfactors in malignant tumors of the salivary glands. Br J Oral MaxillofacSurg 2009;47(8):587-93
Abraham J, Allegra CJ, Gulley JL. Bethesda Handbook of Clinical On-cology. Philadelphia: Lippincott Williams and Wilkins; 2001.
Gettins P, Patston PA, Schapira M. Structure and mechanism of action of serpins. HematolOncolClin North Am 1992 Dec;6(6):1393-408.
Chen WT. Membrane proteases: roles in tissue remodeling and tumor invasion. CurrOpin Cell Biol 1992 Oct;4(5):802-9.
Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994 Jan 28; 263(5146):526-9.
Schneider SS, Schick C, Fish KE, Miller E, Pena JC, Treter SD, et al. A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. ProcNatlAcadSci U S A 1995 Apr 11;92(8):3147-51.
Maass N, Hojo T, Zhang M, Sager R, Jonat W, Nagasaki K. Maspin--a novel protease inhibitor with tumor-suppressing activity in breast cancer. ActaOncol 2000; 39(8):931-4.
Ito R, Nakayama H, Yoshida K, Oda N, Yasui W. Loss of maspin expres-sion is associated with development and progression of gastric carcinoma with p53 abnormality. Oncol Rep 2004 Nov; 12(5):985-90.
Maass N, Hojo T, Ueding M, Luttges J, Kloppel G, Jo-nat W, et al. Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin Cancer Res 2001 Apr; 7(4):812-7.
Li HW, Leung SW, Chan CS, Yu MM, Wong YF. Expression of maspin in endometrioid adenocarcinoma of endometrium. Oncol Rep 2007 Feb; 17(2):393-8.
Abraham S, Zhang W, Greenberg N, Zhang M. Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells. J Urol 2003 Mar; 169(3):1157-61.
Cella N, Contreras A, Latha K, Rosen JM, Zhang M. Maspin is physi-cally associated with [beta]1 integrin regulating cell adhesion in mammary epithelial cells. FASEB J 2006 Jul;20(9):1510-2.
Zhang W, Shi HY, Zhang M. Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins. BMC Cancer 2005 May;20;5:50.:50
Solomon LA, Munkarah AR, Schimp VL, Arabi MH, Morris RT, Nassar H, et al. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. GynecolOncol 2006 Jun;101(3):385-9.
Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW, et al. p53 regulates the expression of the tumor suppressor gene maspin. J BiolChem 2000 Mar 3; 275(9):6051-4.
Khalkhali-Ellis Z. Maspin: the new frontier. Clin Cancer Res 2006 Dec 15; 12(24):7279-83.
Rose SL, Fitzgerald MP, White NO, Hitchler MJ, Futscher BW, De GK, et al. Epigenetic regulation of maspin expression in human ovarian carcinoma cells. Gyneco-lOncol 2006 Aug; 102(2):319-24.
Magdalena Machowska1, Katarzyna Wachowicz13, Mirosław Sopel2 and Ryszard Rzepeck Nuclear location of tumor suppressor protein maspin inhi-bits proliferation of breast cancer cells without affecting proliferation of normal epithelial cells Biomed central( BMC )Cancer 2014, 14:142
Navarro RL, Martins MT, de AraujoVC. Mas-pin expression in normal and neoplastic salivary gland. J Oral Pathol Med 2004;33(7):435-40.
Brandwein MS, Ferlito A, Bradley PJ, Hille JJ, Rinaldo A. Diagnosis and classification of salivary neoplasms: pathologic challenges and relevance to clinical outcomes. ActaOtolaryngol 2002; 122(7):758-64.
de Oliveira FA, Duarte EC, Taveira CT, Maximo AA, de Aquino EC, Alencar RC, et al. Salivary gland tumor: a review of 599 cases in a Brazilian popula-tion. Head Neck Pathol 2009; 3(4):271-5.
Jones AV, Craig GT, Speight PM, Franklin CD. The range and demographics of salivary gland tumours diagnosed in a UK population. Oral oncology 2008; 44(4):407-17.
Ito FA, Ito K, Vargas PA, de Almeida OP, Lopes MA. Salivary gland tu-mors in a Brazilian population: a retrospective study of 496 cases. Int J Oral MaxillofacSurg 2005; 34(5):533-6.
Shishegar M, Ashraf MJ, Azarpira N, Khademi B, Hashemi B, Ashrafi A. Sali-vary gland tumors in maxillofacial region: a retrospective study of 130 cases in a southern Iranian population. Patholog Res Int2011. 934350.
Tian Z, Li L, Wang L, Hu Y, Li J. Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population. Int J Oral MaxillofacSurg 2010; 39(3):235-42.
Gill MS, Mu-zaffar S, Soomro IN, Kayani N, Hussainy AS, Pervez S, et al. Morphological pattern of salivary gland tumours. J Pak Med Assoc 2001; 51(10):343-6.
Li LJ, Li Y, Wen YM, Liu H, Zhao HW. Clinical analysis of salivary gland tumor cases in West China in past 50 years. Oral Oncol 2008; 44(2):187-92.
Vargas PA, Gerhard R, AraujoFilho VJ, de Castro IV. Salivary gland tumors in a Brazilian population: a retrospective study of 124 cases. Rev HospClinFac Med Sao Paulo 2002; 57(6):271-6.
Kayembe MK, Kalengayi MM. Salivary gland tumours in Congo (Zaire). Odontostomatol Trop 2002; 25(99):19-22.
Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 2000 Feb; 6(2):196-9.
Cher ML, Biliran HR, Jr., Bhagat S, Meng Y, Che M, Lockett J, et al. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. ProcNatlAcadSci U S A 2003 Jun 24; 100(13):7847-52.
Klasa-Mazurkiewicz D, Narkiewicz J, Milczek T, Lipinska B, Emerich J. Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients. GynecolOncol 2009 Apr; 113(1):91-8.
Solomon LA, Munkarah AR, Schimp VL, Arabi MH, Morris RT, Nassar H, et al. Maspin expression and localization impact on angioge-nesis and prognosis in ovarian cancer. GynecolOncol 2006; 101(3):385-9.
Lonardo F, Li X, Siddiq F, Singh R, Al-Abbadi M, Pass HI, et al. Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer 2006; 51(1):31-9.
Colmenero RC, Patron RM, Martin PM. Salivary duct carcinoma: a report of nine cases. J Oral MaxillofacSurg 1993; 51(6):641-6.
Yasumatsu R, Nakashima T, Hirakawa N, Kumamoto Y, Kuratomi Y, Tomita K, et al. Maspin expression in stage I and II oral tongue squamous cell carcinoma. Head Neck 2001; 23(11):962-6.
Nakashima D, Uzawa K, Kasa-matsu A, Koike H, Endo Y, Saito K, et al. Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands. Int J Cancer 2006; 118(3):704-13.
Ghazy SE, Helmy IM, Baghdadi HM. Maspin and MCM2 immunoprofiling in salivary gland carcinomas. DiagnPathol 2011; 6:89.
Szanto PA, Luna MA, Tortoledo ME, White RA. Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer 1984; 54(6):1062-9.
Santucci M, BondiR. New prognostic criterion in adenoid cystic carcinoma of salivary gland origin. Am J ClinPathol 1989; 91(2):132-6.
Schwarz S, Ettl T, Kleinsasser N, Hartmann A, Reichert TE, Driemel O. Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncol 2008; 44(6):563-70.
Al-Ayyoubi M, Gettins PG, Volz K. Crystal structure of human maspin, a serpin with antitumor properties: reactive center loop of maspin is exposed but constrained. J BiolChem 2004; 279(53):55540-4.
Al-Ayyoubi M, Schwartz BS, Gettins PG. Maspin binds to urokinase-type and tissue-type plasminogen activator through exosite-exosite interactions. J BiolChem 2007; 282(27):19502-9.
Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ. Biological functions of maspin. J Cell Physiol 2006; 209(3):617-24.
Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, et al. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 2002; 8(9):2924-32
Seftor RE, Seftor EA, Sheng S, Pemberton PA, Sager R, Hendrix MJ. maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res 1998; 58(24):5681-5.
Hojo T, Akiyama Y, Nagasaki K, Maruyama K, Kikuchi K, Ikeda T, et al. Association of maspin expression with the malignancy grade and tumor vascularization in breast cancer tissues. Cancer Lett 2001; 171(1):103-10.
Sheng S, Carey J, Seftor EA, Dias L, Hen-drix MJ, Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. ProcNatlAcadSci U S A 1996; 93(21):11669-74.
Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R. Expression analysis of maspin in invasive ductal carcinoma of breast and modulation of its expression by curcumin in breast cancer cell lines. ChemBiol Interact 2010; 183(3):455-61.
Boltze C. Loss of maspin is a helpful prognosticator in colorectal cancer: a tissue microarray analysis. Pathol Res Pract 2005; 200(11-12):783-90.
Latha K, Zhang W, Cella N, Shi HY, Zhang M. Maspin mediates increased tumor cell apoptosis upon induc-tion of the mitochondrial permeability transition. Mol Cell Biol 2005; 25(5):1737-48.
Odero-Marah VA, Khalkhali-Ellis Z, Chunthapong J, Amir S, Seftor RE, Sef-tor EA, et al. Maspin regulates different signaling pathways for motility and adhesion in aggres-sive breast cancer cells. Cancer Biol Ther 2003;2(4):398-403.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186